Literature DB >> 16916487

Follicular Lymphoma International Prognostic Index.

Philippe Solal-Celigny1.   

Abstract

Although numerous treatment approaches are proposed for patients with follicular lymphoma, criteria to help in choosing a treatment for a given patient and for comparing trial results are lacking. Several retrospective studies have analyzed prognostic factors, but their conclusions rely on limited numbers of patients treated during long periods, and their results are discordant. The Follicular Lymphoma International Prognostic Index was designed from the data recorded over 8 years of nearly 5000 patients registered worldwide. Five factors are used (age, Ann Arbor stage, number of nodal sites, serum lactate dehydrogenase level, and hemoglobin level) to build a three-category index. This index, together with new biologic markers such as gene profiling and proteomics, could help provide an optimal treatment option for patients with follicular lymphoma.

Entities:  

Mesh:

Year:  2006        PMID: 16916487     DOI: 10.1007/s11864-006-0036-3

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  13 in total

1.  Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment.

Authors:  Luca Arcaini; Nora Colombo; Francesco Passamonti; Sara Burcheri; Ester Orlandi; Ercole Brusamolino; Matteo Della Porta; Elisa Rumi; Francesca Montanari; Cristiana Pascutto; Marco Paulli; Mario Lazzarino
Journal:  Leuk Res       Date:  2005-08-19       Impact factor: 3.156

2.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

3.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

Authors:  Wolfgang Hiddemann; Michael Kneba; Martin Dreyling; Norbert Schmitz; Eva Lengfelder; Rudolf Schmits; Marcel Reiser; Bernd Metzner; Harriet Harder; Susanna Hegewisch-Becker; Thomas Fischer; Martin Kropff; Hans-Edgar Reis; Mathias Freund; Bernhard Wörmann; Roland Fuchs; Manfred Planker; Jörg Schimke; Hartmut Eimermacher; Lorenz Trümper; Ali Aldaoud; Reza Parwaresch; Michael Unterhalt
Journal:  Blood       Date:  2005-08-25       Impact factor: 22.113

4.  Long-term results with radiotherapy for Stage I-II follicular lymphomas.

Authors:  R B Wilder; D Jones; S L Tucker; L M Fuller; C S Ha; P McLaughlin; M A Hess; F Cabanillas; J D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-12-01       Impact factor: 7.038

5.  Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems.

Authors:  G Perea; A Altés; S Montoto; A López-Guillermo; E Domingo-Doménech; A Fernández-Sevilla; J M Ribera; J Grau; C Pedro; J Angel Hernández; C Estany; J Briones; R Martino; A Sureda; J Sierra; E Montserrat
Journal:  Ann Oncol       Date:  2005-06-06       Impact factor: 32.976

6.  CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.

Authors:  Robert Marcus; Kevin Imrie; Andrew Belch; David Cunningham; Eduardo Flores; John Catalano; Philippe Solal-Celigny; Fritz Offner; Jan Walewski; Joäo Raposo; Andrew Jack; Paul Smith
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

Review 7.  Prognosis of follicular lymphomas.

Authors:  Philippe Solal-Celigny
Journal:  Clin Lymphoma       Date:  2005-06

8.  Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

Authors:  Michele Ghielmini; Shu-Fang Hsu Schmitz; Sergio B Cogliatti; Gabriella Pichert; Jörg Hummerjohann; Ursula Waltzer; Martin F Fey; Daniel C Betticher; Giovanni Martinelli; Fedro Peccatori; Urs Hess; Emanuele Zucca; Roger Stupp; Tibor Kovacsovics; Claudine Helg; Andreas Lohri; Mario Bargetzi; Daniel Vorobiof; Thomas Cerny
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

9.  Follicular lymphoma international prognostic index.

Authors:  Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat
Journal:  Blood       Date:  2004-05-04       Impact factor: 22.113

10.  Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression.

Authors:  S Montoto; A López-Guillermo; A Altés; G Perea; A Ferrer; M Camós; L Villela; F Bosch; J Esteve; F Cervantes; J Bladé; B Nomdedeu; E Campo; J Sierra; E Montserrat
Journal:  Ann Oncol       Date:  2004-10       Impact factor: 32.976

View more
  9 in total

1.  Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands.

Authors:  Saskia A M van de Schans; Liza N van Steenbergen; Jan Willem W Coebergh; Maryska L G Janssen-Heijnen; Dick Johan van Spronsen
Journal:  Haematologica       Date:  2013-09-13       Impact factor: 9.941

Review 2.  Functional genomics lead to new therapies in follicular lymphoma.

Authors:  Elisa Oricchio; Hans-Guido Wendel
Journal:  Ann N Y Acad Sci       Date:  2013-05-15       Impact factor: 5.691

Review 3.  Follicular Lymphoma: a Focus on Current and Emerging Therapies

Authors:  Kirk E Cahill; Sonali M Smith
Journal:  Oncology (Williston Park)       Date:  2022-02-08       Impact factor: 2.533

4.  Software-automated counting of Ki-67 proliferation index correlates with pathologic grade and disease progression of follicular lymphomas.

Authors:  Mark A Samols; Nathan E Smith; Jonathan M Gerber; Milena Vuica-Ross; Christopher D Gocke; Kathleen H Burns; Michael J Borowitz; Toby C Cornish; Amy S Duffield
Journal:  Am J Clin Pathol       Date:  2013-10       Impact factor: 2.493

5.  Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy.

Authors:  Murali Kesavan; Jan Boucek; William MacDonald; Andrew McQuillan; J Harvey Turner
Journal:  Diagnostics (Basel)       Date:  2017-05-12

6.  The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials.

Authors:  Frederick Lansigan; Ian Barak; Brandelyn Pitcher; Sin-Ho Jung; Bruce D Cheson; Myron Czuczman; Peter Martin; Eric Hsi; Heiko Schöder; Scott Smith; Nancy L Bartlett; John P Leonard; Kristie A Blum
Journal:  Cancer Med       Date:  2018-12-21       Impact factor: 4.452

Review 7.  Prognostic assessment in patients with indolent B-cell lymphomas.

Authors:  Luca Arcaini; Sara Rattotti; Manuel Gotti; Stefano Luminari
Journal:  ScientificWorldJournal       Date:  2012-07-31

8.  Increased activity of cell membrane-associated prothrombinase, fibrinogen-like protein 2, in peripheral blood mononuclear cells of B-cell lymphoma patients.

Authors:  Esther Rabizadeh; Izhack Cherny; Ofir Wolach; Shany Sherman; Natalia Binkovski; Alon Peretz; Doron Lederfein; Aida Inbal
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240

9.  Anemia Associated with Worse Outcome in Diffuse Large B-Cell Lymphoma Patients: A Single-Center Retrospective Study

Authors:  Kenji Matsumoto; Shin Fujisawa; Taiki Ando; Megumi Koyama; Satoshi Koyama; Yoshimi Ishii; Ayumi Numata; Wataru Yamamoto; Kenji Motohashi; Maki Hagihara; Hideaki Nakajima
Journal:  Turk J Haematol       Date:  2018-03-28       Impact factor: 1.831

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.